Skip to content
Trial Eligibility
Menu

Implantable Microdevices for in Situ Evaluation of Drug Responses in Lung Cancer

NCT07892300

This study is recruiting at 1 US site in 1 state, according to its ClinicalTrials.gov record last updated .

Summary

This research is being done to study the safety and feasibility of implanting and retrieving a microdevice that releases microdoses of 20 specific drugs or drug combinations as a possible tool to evaluate the effectiveness of several cancer drugs against lung cancer or mesothelioma.

Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov

Conditions studied

  • Lung Cancer
  • Mesothelioma
  • Suspected Lung Cancer
  • Suspected Mesothelioma

Eligibility basics and study details

Study type
Interventional
Phase
Early Phase 1
Ages
18 years and older
Sex
All
Healthy volunteers
Not accepted
Sponsor
Oliver Jonas
Last updated on ClinicalTrials.gov
November 18, 2026

These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.

US recruiting sites

Massachusetts · 1

  • Brigham and Women's Hospital · Boston, MA

Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.